CFDA approved zytiga for the treatment of metastatic castration resistant prostate cancer

[May 22, 2015, Beijing] - Xi'an Janssen Pharmaceutical Co., Ltd announced today that the State Food and drug administration has approved the drug zytiga, which is the combination of abitrone acetate and prednisone, to treat metastatic castration resistant prostate cancer (mcrpc) Prostate cancer is the second most common cancer among men in the world In 2012, the number of newly diagnosed prostate cancer patients was 1.1 million, accounting for about 15% of the total number of new cancer cases Incidence rate of incidence rate of prostate cancer has been increasing in recent ten years City has become the "most devastated area" of prostate cancer incidence Data show that the incidence rate of prostate cancer in Beijing rose from 5.53/10 million in 2001 to 16.62/10 million in 2010 The incidence rate of prostate cancer increased by more than 10 times in 20 years in Shanghai Prostate cancer is also described as a "silent killer", which is not easy to be found in the early stage Usually, the disease has developed to the late stage when it is diagnosed, and the main symptoms are hematuria, urodynia and osteodynia Prostate cancer is a kind of hormone dependent cancer Androgen plays an important role in the occurrence and development of prostate cancer Androgen deprivation therapy (surgery or drug castration) is one of the most effective treatments for prostate cancer, and it is also the standard treatment for advanced prostate cancer Although the treatment has certain curative effect, the control of tumor can only last for 18 months Then the patient's condition will further develop into castrated resistant prostate cancer (CRPC), and even spread to other organs outside the prostate, such as bone, to become metastatic castrated resistant prostate cancer Professor Sun Yinghao, chairman of the urology branch of the Chinese Medical Association and director of the urology center of the Second Military Medical University, said: "in China, metastatic castration resistant prostate cancer has always been a difficulty in the treatment of advanced prostate cancer In addition to the traditional chemotherapy, there is a lack of effective treatment in China At present, the survival time of patients with metastatic castration resistant prostate cancer is usually less than 2 years, which is very cruel for prostate cancer patients and their families International research shows that the androgen level is further reduced and the survival period of patients can be further prolonged Abitron acetate, a new androgen synthesis inhibitor, can block the androgen synthesis of testis, adrenal gland and tumor itself Its approval in China provides a new choice and a new hope for patients with metastatic castration resistant prostate cancer " Cesar Rodriguez, President of Xi'an Janssen Pharmaceutical Co., Ltd., said: "the approval of Zeke is a milestone for the treatment of metastatic castration resistant prostate cancer patients in China We are very happy to introduce this "breakthrough" treatment plan in China, to do our best to improve the treatment of prostate cancer in China, to help extend the survival time of more prostate cancer patients and improve their quality of life In other countries, we have seen a significant improvement in the quality of life of many patients, and we hope that it can also benefit Chinese patients " Zeke has been approved in 100 countries and has been widely used in more than 170000 prostate cancer patients around the world About Xi'an Janssen Xi'an Janssen is a pharmaceutical subsidiary of Johnson & Johnson, and one of the first pharmaceutical companies to enter China since the reform and opening up Since its establishment in 1985, Xi'an YANGSEN has been committed to the introduction and production of high-quality innovative products to meet the growing demand for medicine and health These products cover mental diseases, neurological diseases, tumor diseases, immune diseases, gastrointestinal diseases and fungal diseases In line with the company's Creed and caring spirit, Xi'an Janssen has been an active corporate citizen and has carried out more than 50 cooperation projects in the fields of medicine, public health, drug research and development and corporate social responsibility